ABSTRACT
INTRODUCTION
Infections caused by Staphylococcus aureus have dramatically increased during the last decade, largely due to the emergence of strains that are resistant to numerous antibiotics and a significant change to the epidemiology of infections caused by this pathogen; namely the emergence of community-acquired (CA) infections [1] . Presentation of disease resulting from either CA or hospital acquired (HA) infections can range from minor skin infections to cellulitis, myositis, or deep bone and tissue infections [1, 2] .
RESULTS, MATERIALS AND DISCUSSION
Previously, we demonstrated that intranasal or subcutaneous immunization of Balb/c mice with LukS-PV (the S component of the Panton Valentine leukocidin; PVL) conferred immunity against lung or skin infection, respectively, with S. aureus USA300 [3] . Immunization with LukF-PV did not confer protection [3] . Surprisingly, both immunization routes elicited cellular immune responses to LukS-PV measured by the significant delayed-type hypersensitivity (DTH) responses elicited in response to LukS-PV following challenge [3] . The antiLukS-PV DTH response was further examined here following infections with either S. aureus USA300 (LAC) or the PVL deletion mutant LAC∆pvl (strains generously provided by Dr. Frank DeLeo, National Institute of Allergy and Infectious Diseases) [4] that were maintained and cultured as described [3] (Figure 1(a) ). Infections with either strain elicited a significant response to inactive α-toxin (H35L) which is expressed by both isolates, but elicitation of DTH was only observed in the mice infected with the LAC strain (Figure 1(a) ).
To further define the role of cellular anti-LukS-PVspecific responses, a LukS-PV-specific T cell line (L S T) was established and tested in vitro and in vivo for reactivity against a panel of peptides ( mice (Harlan, Indianapolis, IN) maintained in vitro as previously described [5] . All animal experiments were approved by the Institutional Animal Care Use Committee at the Texas A&M Health Science Center Institute of Biosciences and Technology. Briefly, L S T were maintained in 24-well plates that contained 1 × 10 6 T cells and 5 × 10 6 mitomycin-treated APCs + 2 µg LukS-PV in a total volume of 1.5 ml complete medium [5] . T cells were cultured for 5 days in 7% CO 2 -93% air incubator at 37˚C. Cells were then pooled, washed, resuspended in complete medium containing 3 U/ml murine recombinant IL-2 (rIL-2 Boehringer-Mannheim) and distributed into 24-well plates at a concentration of 5 × 10 5 cells/ well in a total volume of 1.5 ml complete medium. The cultures were fed every 3 -4 days with complete medium containing 5 U/ml rIL-2 and kept at a cell density of 5 × 10 5 -1 × 10 6 cells/well. T cells were maintained in rest culture for 14 -21 days, after which they were collected, washed and replated in 24-well cell culture plates with fresh mitomycin-treated APCs + 1 µg LukS-PV in a total volume of 1.5 ml complete medium/well. Three days after in vitro stimulation, 3 U of rIL-2 were added to each well. The cultures were then incubated for 3 more days, after which they were put into a rest cycle for another 14 -21 days in medium containing 5 U/ml of rIL-2. At the end of each rest cycle, the T cells were tested for specificity by testing the prol feration response as follows: i 
× 10
4 T cells were cultured in 96-well round-bottom plates along with 1 × 10 5 mitomycin-treated APCs in complete medium in a volume of 100 µl/well in the presence of 0.5 µg/well of LukS-PV. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide, 125 µg/well) was added to the wells and the plate incubated for another 2.5 h at 37˚C. Extraction buffer (50% dimethyl formamide, 20% sodium dodecyl sulfate in water) was added to dissolve the insoluble purple formazan product and the absorbance quantified at 590 nm in a spectrophotometer [5] . Using this procedure, the L S T cell line was generated (Figure 1(b) ). Significant proliferation was observed at 72 and 96 h (P < 0.003, Student's t test) in response to LukS-PV compared to proliferation observed in the respective control groups (Figure 1(b) ). Confirmation that the L S T cell line was CD4 + was carried out by incubating L S T cells with fluorescently-labeled antibodies specific to either CD3, CD4 or CD8. Twocolor flow cytometric analysis demonstrated that the L S T cell line was >98% CD3 + CD4 + (data not shown). LukS-PV peptides were used to challenge mice adoptively transferred with L S T cells (Figure 2(a) ). Mice challenged with peptides 7 (149 -173), 8 (169 -193) or 14 (289 -312) elicited significant responses compared to footpad swelling measurements observed following challenge with the remaining peptides, however, responses observed following challenge with either peptide 7 (149 -173), 8 (169 -193) or 14 (289 -312) were significantly below the response elicited following challenge with LukS-PV (Figure 2(a) ). Interestingly, in vitro stimulation of the L S T cell line with the peptide panel did not reveal as well defined a proliferative response compared to the DTH data described above. Only peptide 8 (169 -193) elicited significantly different proliferation of L S T cells in vitro (Figure 2(b) ). Peptides 7 (149 -173), 10 (209 -233) and 14 (289 -312) elicited slightly elevated proliferative responses over background proliferation in vivo, but these peptides did not significantly stimulate L S T proliferation in vitro (Figure 2(b) ). These data suggest that an epitope contained in the peptide 8 sequence (N 169 YISEVERQNSKSVQWGIKANSFIT 193 ) induced the highest levels of L S T proliferation in vitro and in vivo (in mice adoptively transferred with L S T cells). Further characterization of the epitope present within peptide 8 may further improve the anti-LukS-PV response if used as part of a vaccine.
CONCLUDING REMARKS
Due to the lack of success in human trials utilizing immunogens targeted for their potential to elicit humoral responses, future S. aureus vaccine candidate searches should consider targets with the potential of eliciting protective cellular and humoral responses; a two-pronged immune attack against this pathogen would most likely benefit containment and clearance of cutaneous disease [6] . To what end cellular immune responses may prevent infections or accelerate clearance of this pathogen following infections associated with blood or lung tissues remains to be examined, however, cellular responses, particularly those associated with elevated production of INFg are beneficial in protection against various types of S. aureus infections [7] [8] [9] . It is likely, that vaccine-mediated induction of cellular immunity may bolster antibody responses generated following exposure (whether from infection, carriage, or contact) to S. aureus.
